Alkermes Launches New Website Offering Education About Alcohol Dependence
Dublin-headquarted biopharma Alkermes has launched a new website to offer education about alcohol dependence. Myrelationshipwithalcohol.com offers educational information about alcohol dependence, an interactive questionnaire developed by the National Institutes of Health (NIH) designed to assess personal drinking patterns, and a discussion guide to help start a conversation with healthcare providers about the disease and treatment options.
"As one of the few companies working in this disease area, we felt compelled to develop a resource to help people better understand alcohol dependence," commented Blair Jackson, Executive Vice President, Chief Operating Officer of Alkermes. ”Despite its prevalence, understanding of the disease itself and awareness of approved treatment options that exist remain low. Our aim is to provide people who may be living with the disease, or those who are caring for people living with it, with information to help empower them to speak with a healthcare provider.”
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
